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Abstract
Background: Central to the pathogenesis of Alzheimer’s disease (AD) and many other neurodegenerative diseases
is the conformational change of a normal self-protein into toxic oligomeric species and amyloid deposits. None of
these disorders have an effective therapy, but immunization approaches hold great promise. We have previously
shown that active immunization with a novel peptide when polymerized into a stable oligomeric conformation,
pBri, induced a humoral immune response to toxic Aβ species in an AD model, APP/PS1 transgenic (Tg) mice,
reducing plaque deposits. pBri is a glutaraldehyde polymerized form of the carboxyl fragment of an amyloidogenic
protein, which is deposited in the brains of patients with a rare autosomal dominant disease due to a missense
mutation in a stop codon, resulting in the translation of an intronic sequence, with no known sequence homology
to any mammalian protein.
Methods: In the current study we tested whether pBri-peptide-based immunomodulation is effective at reducing
both vascular amyloid deposits and tau-related pathology using TgSwDI mice with extensive congophilic angiopathy
and 3xTg mice with tau pathology.
Results: Our results indicate that this immunomodulation approach, which produces a humoral response to proteins in
a pathological conformation, is effective at reducing both Aβ and tau-related pathologies.
Conclusions: This immunomodulatory approach has the advantage of using a non-self-immunogen that is less likely
to be associated with autoimmune toxicity. Furthermore we found that it is able to target all the cardinal features of
AD concurrently.
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Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia globally, affecting approximately 36 million
people currently and approximately 115 million by 2050
[1]. Presently available treatments have minimal or no ef-
fect on the course of the disease. Numerous novel thera-
peutic strategies are being developed, with active and
passive immunization being among the most advanced ap-
proaches [2-6]. The neuropathology of AD consists of the
accumulation of amyloid β (Aβ) as amyloid plaques and
congophilic amyloid angiopathy (CAA), as well as the ac-
cumulation of aggregated, phosphorylated tau as neurofib-
rillary tangles [7]. The most toxic species of Aβ and
aggregated tau are thought to be oligomeric, with both of
these pathologies potentially spreading via extracellular
soluble oligomers in a prion-like mechanism [8-10]. Aβ
and tau oligomers, as well as amyloid plaques and neuro-
fribrillary tangles (NFTs), share many structural and
biophysical properties, such as a high β-sheet content,
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resistance to proteolytic degradation and neuronal toxicity.
It has also been shown that Aβ and tau-related pathology
can, under some conditions, seed or propagate each other.
Immunotherapy is very effective for both AD and prion
diseases, at least in mouse models [11,12]. Unfortunately,
two recent phase III trials of passive immunization for AD
failed to achieve benefit by their primary end points [13].
To develop a highly successful immunotherapy for AD pa-
tients, several problems need to be overcome including:
avoiding excessive cell-mediated immunity, which has been
linked to autoimmune encephalitis; reducing CAA depos-
ition without inducing associated microhemorrhages and/
or vasogenic edema; reducing tau-related pathology, which
is known to correlate with clinical status better than amyl-
oid deposits, and targeting of oligomeric species, which are
the most toxic [3]. To concurrently address all these issues
we sought to develop therapeutic immunomodulation
through a novel active immunization approach that specif-
ically targets the pathological β-sheet conformation that is
shared by Aβ and tau-disease-associated species. We used
a polymerized British amyloidosis (pBri) related peptide in
a predominantly β-sheet, in an oligomeric form, prepared
using glutaraldehyde in a controlled manner. British amyl-
oidosis (ABri) is a rare form of familial human amyloidosis
associated with a missense mutation in a stop codon. This
mutation results in the transcription of an intronic se-
quence, leading to the production of a highly amyloido-
genic protein with a carboxyl terminus that has no
sequence homology to any other native human protein, in-
cluding Aβ and tau [14-16].
We hypothesized that through conformational mim-
icry the polymerized oligomeric pBri peptide, which cor-
responds to the carboxyl terminus of ABri, could induce
a conformation-selective immune response that will
recognize Aβ, as well as aggregated phosphorylated tau.
Such an immunostimulatory approach would have a re-
duced risk of inducing autoimmune complications as it
is specific to pathological conformers and the immuno-
gen has no sequence homology to any known mamma-
lian protein or peptide. In a prior study we tested this
approach in an APP/PS1 AD mouse model with exten-
sive amyloid plaque deposition [16] and evaluated for
behavioral benefits and reductions in Aβ-related path-
ology histologically and biochemically. We showed that
this immunomodulation targeting a pathological con-
formation of Aβ was highly effective at reducing amyloid
plaques, correlating with behavioral rescue. The poly-
clonal antibody response obtained in the vaccinated
mice specifically recognized plaques and dystrophic
neurites in human brain tissue [16]. This novel thera-
peutic approach was commented on as a promising new
direction for AD vaccination [17]. In the current study
we addressed the critical issues of whether this type of
approach could be used for both CAA and tau-related
pathology, without any associated toxicity. To assess for
effects on vascular amyloid and NFT-related pathology we
used TgSwDI mice, which are a well-characterized model
of CAA, and 3xTg mice with tau pathology, respectively
[18,19]. We hypothesized that for immunomodulation to
be highly successful it needs to target all the cardinal le-
sions of AD concurrently, that is amyloid plaques, CAA
and NFT. Furthermore, to reduce the possibility of auto-
immune complications, the immunogen needs to be a
non-self-antigen in a conformation that induces an im-
mune response that specifically targets pathological con-
formers. The evaluation of the effectiveness of our novel
immunomodulatory approach in a variety of AD mouse
models, which mimic different aspects of the human dis-
ease, is a critical step before any clinical testing.
Materials and methods
Synthesis of peptide, polymerization of the Bri peptide
and assessment of conformation
This was done as previously published [16]. In brief, the 13
residue peptide corresponding to the carboxyl terminus of
ABri (Cys-Ser-Arg-Thr-Val-Lys-Lys-Asn-Ile-Ile-Glu-Glu-Asn)
was synthesized on an ABI 430A peptide synthesizer
(AME Bioscience, Chicago, IL) at the Keck peptide syn-
thesis facility at Yale University, CT. Mass spectroscopy
of the lyophilized end-product was used to verify the
expected molecular weight. To make the 13-residue Bri
peptide immunogenic and to have a stable oligomeric
conformation, the peptide was subjected to controlled
polymerization using the following protocol.
The peptide was dissolved at 3 mg/ml, in 100 mM borate
buffer saline (BBS), pH 7.4. Fresh 1% glutaraldehyde in
BBS was prepared and added to the peptide to a final
5 mM glutaraldehyde concentration and incubated in an
Eppendorf block shaker at 800 rpm and 56°C for 16 h. The
solution was then quenched with 0.5 M glycine to make
the solution 100 mM in glycine. After 5 min, the solution
was diluted 1:3 with BBS, dialyzed against 2 mM BBS over-
night at 4°C, aliquoted and lyophilized. To determine the
degree of aggregation the original monomeric Bri peptide
and polymerized Bri (pBri) were electrophoresed on 12.5%
sodium dodecyl sulfate (SDS)-polyacrylamide tris-tricine
gels under reducing conditions. Western blots were per-
formed with a rabbit anti-ABri polyclonal Ab [16] (1:1,000
dilution). The secondary antibody (1:2,000 dilution) was
peroxidase-linked anti-rabbit IgG (Amersham Biosciences,
Piscataway, NJ), and the immunoreactive material was
visualized as chemoluminescence on X-ray film with the
enhanced chemiluminescence (ECL) detection kit (Pierce).
For electron microscope studies, the original and polymer-
ized Bri peptides were incubated at 1 mg/ml in phosphate-
buffered saline, pH 7.4. Next, 3 μl of sample was put onto
a carbon-coated 400 mesh Cu/Rh grid (Ted Pella, Inc,
Redding, CA) and stained with 1% uranyl acetate in
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distilled water (Polysciences, Inc, Warrington, PA), as
previously published [16]. For secondary structure analysis,
aliquots of the original Bri peptide and pBri were reconsti-
tuted in 5 mM tris buffer (pH 7.0) to obtain a peptide
concentration of 100 μM. Circular dichroism was mea-
sured on a Jasco J-720 spectropolarimeter (Easton, MD)
equipped with a model CTC-344 circular temperature con-
trol system (Neslab Inc, Newington, NH).
Immunization of mice
Animal studies were approved by the New York
University School of Medicine Institutional Animal Care
and Use Committee and were consistent with the recom-
mendations of the American Veterinary Association.
Mice facilities were under a strict 12 h light/dark cycle.
Triple transgenic (3xTg) mice (PS1M146V, tauP301L and
APPK670N/M671L) are a model of combined tau- and
amyloid-related pathology [19,20]. To model vascular
amyloid deposition, the well-characterized TgSwDI
mouse model was used [21,22]. This model expresses the
APPE693Q/D694N (Dutch and Iowa) and APPK670N/
M671L (Swedish) mutations. The pBri peptide was
dissolved in sterile saline at 1 mg/ml and mixed 4:1
with aluminum hydroxide (alum) adjuvant (Brenntag
Biosector, Denmark). Each mouse received a weekly sub-
cutaneous injection of 100 μl of the preparation (50 μg of
pBri) for 4 weeks, starting at the age of 3 months,
followed by an inoculation a month later and two subse-
quent bimonthly injections. The last three inoculations
used 25 μg of pBri per animal and the ratio of saline to
alum was changed to 9:1. Both the 3xTg and TgSwDI
mice were divided into two groups of 14 mice each.
There were equal numbers of males and females in each
experimental group. For each transgenic line, one group
received pBri immunization while the second control
group received vehicle injections (alum alone). The mice
were subject to behavioral testing at the age of 15 to
16 months.
Sensorimotor and cognitive testing
Sensorimotor and cognitive testing were done as previ-
ously described [16,20,22]. Prior to testing, the mice
were adapted to the room with lights on for 15 min. The
main objective of performing these sensorimotor tasks
was to verify that any treatment-related effects observed
in the cognitive tasks could not be explained by differ-
ences in sensorimotor abilities.
Locomotor activity
A Hamilton-Kinder Smart-frame Photobeam System was
used to make a computerized recording of animal activ-
ity over a designated period of time. Exploratory loco-
motor activity was recorded in a circular open-field
activity chamber measuring 70 cm in diameter. A video
camera mounted above the chamber automatically re-
corded horizontal movements in the open field in each
dimension. Total distance was measured in centimeters
traveled and is defined as the sum of sequential move-
ment between interruptions of the animal. The duration
of the behavior was timed over 15 min. Results were re-
ported based on distance traveled (cm), mean resting
time and maximum speed of the animal.
Traverse beam
This task tests balance and general motor coordination
and function integration. Mice were assessed by measur-
ing their ability to traverse a graded narrow wooden
beam to reach a goal box. This specifically examines
hind limb function. The mice were placed on a 1.1 cm
wide beam, 50.8 cm long, supported 30 cm above a pad-
ded surface on two identical columns. A shaded goal
box was attached at each end of the beam. Mice were
placed on the beam in a perpendicular orientation to ha-
bituate, and were then monitored for a maximum of
60 sec. The number of foot slips each mouse made be-
fore falling or reaching the goal box was recorded for
each of three successive trials. The average number of
foot slips for all three trials was calculated and recorded.
Errors are defined as foot slips and were recorded both
numerically and using Feeney scores. To prevent injury
from falling, a soft foam cushion was always kept under-
neath the beam. Animals that fell off were placed back
in the position they were in prior to the fall.
Rotarod
Each animal was placed onto a rod (diameter 3.6 cm) ap-
paratus to assess differences in motor coordination and
balance by measuring fore- and hindlimb motor coordin-
ation and balance (Rotarod 7650 accelerating model; Ugo
Basile, Biological Research Apparatus, Varese, Italy). This
was designed to assess motor behavior without a practice
confound. The animals were habituated to the apparatus
by receiving training sessions of two trials, which was suf-
ficient to reach a baseline level of performance. The mice
were tested a further three times, with increasing speed.
During habituation, the rotor rod was set at 1.0 rpm,
which was gradually increased every 30 sec to a maximum
speed of 40.0 rpm. The rod was wiped clean with 30%
ethanol solution after each session. A soft foam cushion
was placed beneath the apparatus to prevent potential in-
jury from falling. Each animal was tested for three ses-
sions, with each session separated by 15 min. The latency
to fall or invert (by clinging) from the top of the rotating
barrel was recorded.
Radial arm maze
Spatial learning was evaluated using an eight-arm radial
maze with a water well at the end of each arm, as we
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have previously published [16,20,22], for both TgSwDI
and 3xTg mice. For each group of transgenic mice, an
age-matched control group of non-transgenic mice (n =
10) were also tested in the radial arm maze. Clear Plexi-
glas guillotine doors, operated by a remote pulley sys-
tem, controlled access to the arms from a central area
from which the animals entered and exited the appar-
atus. After 4 days of adaptation to the maze, water-
restricted mice (only given access to water 2 h per day)
were given one training session per day for 10 consecu-
tive days. We use this relatively long adaptation period
as we have found that these transgenic (Tg) AD mice
tend to be anxious and will not run the maze well with-
out adaptation [16,20,22]. Prior to each day’s testing,
the mice were adapted to the room with the lights on
for 15 min. For each session, all arms were baited with
saccharine-flavored water, and the animals were per-
mitted to enter all arms until the eight rewards had
been consumed. The number of errors (entries to pre-
viously visited arms) and time to complete each session
were recorded.
Antibody levels
Antibody levels were determined in duplicate on 1:100
dilutions of plasma using ELISA as described previously
[16,20,22], in which 50 μg/plate aggregated Aβ1-42,
aggregated Aβ1-40, pBri or purified human paired
helical filaments (PHF) was coated onto Immulon 2HB
96-well microtiter wells (Thermo, Waltham, MA). The
human PHF was prepared and characterized for purity
by Western blotting with PHF1 and electron micros-
copy, as previously published [16]. The bound antibodies
were detected by a horseradish peroxidase-labeled goat
anti-mouse IgG (Amersham Biosciences, Piscataway, NJ)
or a peroxidase conjugated goat anti-mouse IgM (Sigma;
A8786). The color developing substrate was tetramethyl-
benzidine (TMB) (Pierce, Rockford, IL) and the readings
were made at 450 nm.
Histology
The mice were anesthetized with sodium pentobarbital
(150 mg/kg, intraperitoneally), perfused transaortically
with phosphate buffer, and the brains processed as de-
scribed previously [16,20,22]. The right hemisphere was
immersion-fixed in periodate-lysine-paraformaldehyde,
whereas the left hemisphere was snap-frozen for measure-
ments of Aβ levels in both transgenic lines and phosphor-
ylated tau in the 3xTg mice. Serial coronal sections
(40 μm) were cut (30 to 40 sections in total), and every
fifth section was stained with a mixture of 4G8 and 6E10,
which are monoclonal antibodies that recognize Aβ and
stain both pre-amyloid and Aβ plaques [23,24]. In 3xTg
mice, the degree of tau-related pathology was determined
with anti-abnormally phosphorylated tau monoclonal
antibodies PHF1 (which recognizes phosphorylated serine
in position 396 and 404) [25] and AT8 (which recognizes
tau phosphorylated at both serine 202 and threonine 205)
[26]; these antibodies were kindly provided by Dr Peter
Davies from the Albert Einstein College of Medicine,
Bronx, NY.
Glial fibrillary acidic protein (GFAP) is a component
of the glial intermediate filaments that forms part of the
cytoskeleton and is found predominantly in astrocytes.
CD45 is a protein tyrosine phosphatase, commonly used
to detect microglial activation at the later stages of
plaque development [27,28]. Two series of sections were
immunostained with anti-GFAP (Dako, Carpinteria, CA)
and anti-CD45 (Abd Serotec, Raleigh, NC) antibodies.
Immunostaining was performed as described previ-
ously [16,20,22]. Briefly, sections were incubated in 6E10/
4G8 each at a 1:1000 dilution in PBS-T for 3 h. A mouse-
on-mouse immunodetection kit (Vector Laboratories,
Burlingame, CA) was used. The sections were incubated
first with biotinylated anti-mouse IgG secondary anti-
body for 1 h at a 1:2000 dilution and later with the
avidin-peroxidase complex for 30 min at the same dilu-
tion. The sections were then reacted in 3,3-diaminoben-
zidine tetrahydrochloride with nickel ammonium sulfate
(Mallinckrodt, Paris, KY) color intensification solution.
Immunohistochemistry of 6E10/4G8 immunolabeled tis-
sue sections was quantified with a Bioquant image ana-
lysis system (BIOQUANT Image Analysis Corporation,
Nashville, TN), and unbiased sampling was used [24]. All
procedures were performed by an individual blinded to
the experimental conditions of the study.
The cortical area analyzed was dorsomedial from the
cingulate cortex and extended ventrolaterally to the rhinal
fissure within the right hemisphere. The area of the grid
was 800 × 800 μm2, and the Aβ deposit load was measured
for 20 cortical frames per mouse (640 × 480 μm2 each)
chosen randomly. The threshold of the Aβ immunoreac-
tive areas was set so that areas of <5 μm in diameter are
not counted. This was done so that small artifactual areas
of staining were not counted and the intra-neuronal im-
munoreactivity was also not counted. With the latter cav-
eat, the Aβ burden was defined as the percentage of the
area in the measurement field occupied by the reaction
product. GFAP-staining (polyclonal, 1:1000; 3 h, Dako,
Denmark) was performed with a primary antibody diluent
composed of 0.3% triton X-100, 0.1% sodium azide, 0.01%
bacitracin, 1% bovine serum albumin (BSA) and 10% nor-
mal goat serum in PBS, and a secondary biotinylated goat
anti-rabbit antibody (Vector Laboratories, Burlingame,
CA) reacted for 1 h at 1:1000 dilution. The analysis of the
CD45 immunohistochemistry (rat anti-mouse, 1:500; 3 h,
Serotec) was performed like the GFAP-staining except
that the secondary antibody was goat anti-rat (Vector
Laboratories, Burlingame, CA) diluted 1:1000.
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The tau burden was analyzed based on the extent of
immunostaining with two anti-tau antibodies, PHF1 and
AT8, as previously described [20]. PHF1 was analyzed at
10× magnification in both the hippocampus and cortex.
Approximately six sections were analyzed per animal. AT8
was analyzed at 10× magnification for the hippocampus
(AT8 was not analyzed in the cortex as the cortical
AT8 immunolabeling was minimal). Approximately eight
cortical sections and six hippocampal sections were ana-
lyzed per animal. The rating was based on the number of
reactive neuronal bodies and processes. Reactive astrocyto-
sis (GFAP immunoreactivity) was rated on a scale of 0 to 4.
The rating was based on a semiquantitative analysis of the
extent of GFAP immunoreactivity (the number of GFAP



















































































































































































































Figure 1 Plasma antibody levels to aggregated Aβ40, Aβ42 and pBri in pBri-vaccinated mice. Shown are bar graphs of the IgM and IgG
antibody levels of (A) TgSwDI and (B) 3xTg and against Aβ40, Aβ42 and pBri at T0 (before vaccination), T1 (after the fourth inoculation) and Tf
(at the time of sacrifice). Plasma samples were evaluated at a dilution of 1:100 in duplicate. (*P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001 by unpaired
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Figure 2 Antibody titers in plasma reactive against purified human paired helical filaments (PHF) at Tf and characterization of the PHF
preparation. Titers for the TgSwDI and 3xTg mice were determined against human purified PHF at Tf for both IgM and IgG and were compared
to vehicle-inoculated Tg controls. Shown are the titers for TgSwDI IgM (A), TgSwDI IgG (B), 3xTg IgM (C) and 3xTg IgG (D). These differences in
titer are statistically significant by two-way unpaired t-tests (P = 0.0038, P = 0.0037, P = 0.0057 and P = 0.04, respectively). (E) Western blot of the
human PHF sample used to seed the ELISA plates in (A) to (D). (F) Electron micrograph of the human PHF sample used, revealing the expected
paired helical filaments. OD, optical density; Tg, transgenic.
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immunoreactive cells and complexity of astrocytic
branching), as we have previously published [16,20,22].
The assessment of the CD45 immunostained sections
was based on a semiquantitative analysis of the extent
of microgliosis (0, no microglia; 1, a few resting micro-
glia; 2, a few ramified and/or phagocytic microglia; 3,
moderate number of ramified/phagocytic microglia; 4,
numerous ramified/phagocytic microglia), as we have
previously reported [16,20,22].
Perl’s iron staining was performed for the TgSwDI mice
on another set of sections to detect cerebral microhemor-
rhages, as we have previously reported [22]. Sections were
stained in a solution containing 5% potassium ferrocyan-
ide and 10% hydrochloric acid for 40 min.
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B  3xTg mice
Figure 3 Cognitive testing of TgSwDI and 3xTg mice using a radial arm maze. The number of errors is plotted versus the day of testing.
(A) Results for TgSwDI mice. (B) Results for 3xTg mice. There are no differences between the wild-type controls and the pBri-treated TgSwDI mice.
There are statistically significant differences between the vehicle control mice and the pBri-treated TgSwDI mice and wild-type controls using
two-way ANOVA, and the treatment effect had P < 0.001. Newman–Keuls post hoc analyses indicate that both the wild-type controls and
pBri-vaccinated Tg mice were significantly different from the control Tg mice (P < 0.001). There are no differences between the wild-type controls
and the pBri-treated 3xTg mice. There are statistically significant differences between the vehicle control mice and the pBri-treated 3xTg mice
and wild-type controls using two-way ANOVA, and the treatment effect had P < 0.001. Newman–Keuls post hoc analyses indicate that both the









Figure 4 Quantitation of Aβ burden in the hippocampus of TgSwDI mice. Representative brain sections of both (A) vehicle control and
(B) pBri-treated Tg mice immunostained with anti-Aβ antibodies 4G8 and 6E10 from the hippocampus. (C) Bar graph of amyloid burden calculated
using stereology for the hippocampus of vehicle control and pBri-vaccinated TgSwDI mice. On average there was a 42% reduction in the areas
occupied by 4G8/6E10 immunoreactivity (*P = 0.039 by an unpaired two-tailed t-test). Tg, transgenic.










Figure 5 Quantitation of Aβ burden in the cortex of TgSwDI mice. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg
mice immunostained with anti-Aβ antibodies 4G8 and 6E10 from the cortex. (C) Bar graph of amyloid burden calculated using stereology for the cortex
of vehicle control and pBri-vaccinated TgSwDI mice. On average there was a 70% reduction in the areas occupied by 4G8/6E10 immunoreactivity









Figure 6 Quantitation of amyloid burden in the amygdala of TgSwDI mice. Representative brain sections of both (A) vehicle control and
(B) pBri-treated Tg mice immunostained with anti-Aβ antibodies 4G8 and 6E10 from the amygdala. (C) Bar graph of amyloid burden calculated
using stereology for the amygdala of vehicle control and pBri-vaccinated TgSwDI mice. On average there was a 72% reduction in the areas
occupied by 4G8/6E10 immunoreactivity accounting for precipitated amyloid (*** P < 0.0004 by an unpaired two-tailed t-test). Tg, transgenic.
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Tissue homogenization and sandwich ELISA assay for
soluble Aβ levels
Aβ was extracted from brain tissue as described [24] for
both TgSwDI and 3xTg mice. Brains were weighed and ho-
mogenized (20% w/v) in a homogenization buffer, 20 mM
Tris, 250 mM sucrose, 1 mM Ethylenediaminotetraacetic
acid disodium salt (EDTA), 1 mM Ethylene glycol tetra-
acetic acid tetrasodium salt (EGTA) with freshly pre-
pared 100 mM phenylmethylsulfonyl fluoride, 5 μg/ml
pepstatin A and a protease inhibitor cocktail (Complete,
Roche Diagnostics, Indianapolis, IN). Subsequently, 400 μl









Figure 7 Quantitation of amyloid burden in the hippocampus of 3xTg mice. Representative brain sections of both (A) vehicle control and
(B) pBri-treated Tg mice immunostained with anti-Aβ antibodies 4G8 and 6E10 from the hippocampus. (C) Bar graph of hippocampus burden
calculated using stereology for the hippocampus of vehicle control and pBri-vaccinated 3xTg mice. On average there was a 71% reduction in the
areas occupied by 4G8/6E10 immunoreactivity accounting for precipitated amyloid (***P = 0.0006 by an unpaired two-tailed t-test). Tg, transgenic.













Figure 8 Levels of soluble Aβ40 and Aβ42 in 20% brain homogenates. (A) TgSwDI treated and Tg control groups show a 31% and 34%
reduction in the levels of Aβ40 (*P = 0.02) and Aβ42 (*P = 0.01). (B) There was a 55% and 84% reduction in the levels of Aβ40 (***P < 0.0001) and
Aβ42 (***P = 0.0004) between 3xTg treated and vehicle control groups, respectively. P values are by unpaired two-tailed t-tests. Tg, transgenic.
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aliquoted, flash-frozen on dry ice and stored at -80°C until
used for both Aβ and tau measurements in ELISA and
Western blots.
The total and soluble Aβ levels were measured using a
combination of mouse monoclonal antibody 6E10 (spe-
cific to an epitope present on amino acid residues 1 to
16 of Aβ) and two different rabbit polyclonal antibodies
specific for Aβ40 (R162) and Aβ42 (R165), in a double-
antibody sandwich ELISA as described previously
[23,24]. The optical density (OD) was measured at
450 nm. The relation between OD and Aβ peptide con-
centration was determined by a four-parameter logistic
log function. Non-linear curve fitting was performed



















































Figure 9 Quantitation of Aβ oligomers. Oligomer levels in the soluble brain fractions were determined using an ELISA specific to aggregated/
oligomeric Aβ. Two-tail unpaired t-tests of this ELISA data show a significant reduction of levels of Aβ aggregates/oligomers for the pBri-treated
group vs. the vehicle group for both (A) TgSwDI mice (35% reduction) and (B) 3xTg mice (37% reduction) (*P = 0.02 and *P = 0.04, respectively,









Figure 10 Quantitation of tau burden using PHF1 for the hippocampus of 3xTg mice. The tau burden was analyzed semiquantitatively on
a scale of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with PHF1 from the
hippocampus. (C) Bar graph of tau semiquantitative analysis for the hippocampus of Tg control and pBri-vaccinated mice. On average there was
a 74% reduction in the areas occupied by PHF1 immunoreactivity accounting for phosphorylated tau (***P = 0.0005 by an unpaired two-tailed
t-test). Tg, transgenic.
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Winooski, VT) to convert the OD of plasma to esti-
mated concentrations. The assay was performed by an
investigator blinded to group assignment. The levels of
Aβ species are presented as micrograms of Aβ per gram
of wet brain, taking into account dilution factors intro-
duced by multiple steps throughout the assay (brain
homogenization and extraction procedures).
Western blot and Meso Scale Discovery
electrochemiluminescence analysis of phosphorylated tau
for 3xTg mice
For Western immunoblot analysis, 20% w/v brain homog-
enates from the 3xTg mice were centrifuged at 25,000 g
for 10 min at 4°C, and the supernatants were transferred
to clean tubes and stored as previously described [23,24].
The total protein concentration in the supernatant was
determined using the bicinchoninic acid assay (Pierce,
Rockford, IL). Samples (40 μg of total protein) were mixed
with an equal volume of tricine sample buffer (BioRad,
Hercules, CA), electrophoresed on 12.5% SDS-tris-tricine
polyacrylamide gels under non-reducing conditions and
transferred to nitrocellulose membranes. To assess wheth-
er there was equal protein loading in each lane, the mem-
branes were stained with reversible 0.1% Fast Green FCF
(Fisher Scientific, USA) in 25% methanol destained in 25%
methanol and transferred to distilled water. The blots were
then blocked with 5% non-fat dry milk in 50 mM tris buf-
fer saline- 0.1% Tween 20 (TBS-T), pH 8.3, for 2 h at room
temperature, then incubated with PHF1 diluted 1:500 in
TBS-T, 0.1% BSA for 2 h at room temperature. Bound
antibodies were detected after 1 h incubation with horse-
radish peroxidase-conjugated goat anti-mouse IgG 1:8000
(Pierce, Rockford, IL) and the ECL detection system
(Pierce, Rockford, IL). The specificity of the PHF1 band
was confirmed by Western blots using homogenates of
non-transgenic mouse brains. Only the bands detected by
PHF1 in 3xTg transgenic mouse homogenates and not in
the non-transgenic mouse homogenates were quantitated.
Densitometric analysis of the PHF1 specific bands was per-
formed with the NIH Image J software version 1.34.
The same 20% brain homogenates containing only sol-
uble forms of tau were centrifuged at 100,000 g. Total tau
and phosphorylated tau (Thr231) were quantified using a
Meso Scale Discovery (MSD) (Rockville, MD) system that
utilizes electrochemiluminescence analysis. The multi-
array phospho (Thr231) tau assay kit, which measures
both total human tau and phosphorylated Thr231 tau, was
used with the MesoQuickPlex SQ 120 system, following
the manufacturer’s instructions. In brief, samples were di-
luted 1:125 with the provided standard diluent buffer and
100 μl aliquots were seeded in each well. The plates were









Figure 11 Quantitation of tau burden using PHF1 for the cortex of 3xTg mice. The tau burden was analyzed semiquantitatively on a scale
of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with PHF1 from the cortex.
(C) Bar graph of tau semiquantitative analysis for the cortex of Tg control and pBri-vaccinated mice. On average there was a 75% reduction in the
areas occupied by PHF1 immunoreactivity accounting for phosphorylated tau (***P = 0.0017 by an unpaired two-tailed t-test). Tg, transgenic.
Goñi et al. Journal of Neuroinflammation 2013, 10:150 Page 10 of 22
http://www.jneuroinflammation.com/content/10/1/150
times for 25 sec each, before the Hu Aggregated Aβ biotin
conjugate was added and incubated for 1 h. The plates
were again washed four times and the Streptavidin-HRP
working solutions was added. The plates were covered to
block the light and incubated for 25 min before the reac-
tion was stopped with the stop solution. The plates were
read on the MSD system at 450 nm. All data were re-
corded and calculations made using the software provided
with the MSD system.
Quantitation of aggregated/oligomeric Aβ
Aggregated/oligomeric Aβ levels were determined using the
Human Aggregated Aβ ELISA kit (Invitrogen, Camarillo,
CA), following the manufacturer’s instructions. In brief, the
levels of aggregated/oligomeric Aβ in each sample were
measured against a standard containing aggregated Aβ. Next
20% w/v brain homogenates were thawed, diluted 1:4 with
the diluents buffer and applied to the ELISA plates. The
samples were then incubated for 2 h at room temperature
allowing the N-terminal portion of the Aβ to bind the
pre-coated capture monoclonal antibody, followed by exten-
sive washing and incubation for 1 h at room temperature
with biotin conjugated detection antibodies (same as the
capture antibody), which binds only to the immobilized ag-
gregated Aβ. After removal of excess antibody, horseradish
peroxidase-labelled streptavidin was added. The sample was
incubated for 30 min, followed by washing and TMB sub-
strate incubation to produce color. The intensity of this
colored product is directly proportional to the concentration
of aggregated/oligomeric Aβ in the sample. The standards
produced a linear curve and the best-fit lines determined by
linear regression were used to calculate aggregated Aβ con-
centrations in the samples.
Statistical analysis
Data from the accelerating rotor rod and locomotor test
were analyzed using two-tail, Student’s t-tests. The data
collected from the radial arm maze test was analyzed
using two-way ANOVA, and also by one-way ANOVA
followed by Newman–Keuls post hoc tests. Differences
in total amyloid burden, levels of extracted Aβ, levels of
Aβ aggregates/oligomers, tau burden, astrogliosis and
microgliosis between the two groups were analyzed
using two-tailed t-tests. All statistical tests were per-
formed using Prism 6.0 (Graphpad, San Diego, CA).
Results
Antibody titers for Aβ40, Aβ42, pBri and human purified PHF
For both the TgSwDI strain (Figure 1A) and the 3xTg









Figure 12 Quantitation of tau burden using AT8 for the hippocampus of 3xTg mice. The tau burden was analyzed semiquantitatively on a
scale of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with AT8 from the hippo-
campus. (C) Bar graph of tau semiquantitative analysis for the hippocampus of Tg control and pBri-vaccinated mice. On average there was a 55%
reduction in the areas occupied by AT8 immunoreactivity accounting for phosphorylated tau (*P = 0.03 by an unpaired two-tailed t-test).
Tg, transgenic.
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IgG and IgM titers at T1 (after the fourth inoculation) and
Tf (at the time of sacrifice) against aggregated Aβ40, aggre-
gated Aβ42 and polymerized Bri, compared to equivalent
T0 titers (prior to vaccination) by two-tailed unpaired
t-tests. In the control groups for both TgSwDI and 3xTg
strains, as expected, there were no significant differences in
T1 and Tf titers against Aβ40, Aβ42 and pBri versus T0,
with OD values all being ≤0.03 (data not shown).
Titers for the TgSwDI and 3xTg mice were determined
against human purified PHF at Tf for both IgG and IgM
and were compared to titers for vehicle-inoculated
Tg controls at Tf: TgSwDI IgM (Figure 2A), TgSwDI
IgG (Figure 2B), 3xTg IgM (Figure 2C) and 3xTg
IgG (Figure 2D). These differences in titer are statisti-
cally significant by two-way unpaired t-tests (P = 0.0038,
P = 0.0037, P = 0.0057 and P = 0.04, respectively). Char-
acterization of the PHF preparation used for the Western
blot and electron microscopy is shown in Figure 2E and
F, respectively.
Figure 2E shows a Western blot of the human PHF sam-
ple that was used to seed the ELISA plates shown in
Figure 2A to D. For the Western blot, Aβ1-42 (2 μg) was
loaded into lane 1 and sonicated human PHF (5 μg) was
loaded into lane 2. The membrane of lanes 1 and 2 was
developed with PHF1 monoclonal antibodies at a dilution
of 1:2000. The film was exposed for 60 sec. No cross-
reactivity of the PHF1 antibody with Aβ species can be
seen in lane 1. The human PHF preparation consisted of
species varying from 50 kDa to more than 200 kDa, plus
aggregates of higher molecular weight seen at the top of
the gel, as identified by PHF1 in lane 2. Then 5 μg of the






























Total Tau by MSD
no significant difference













Figure 13 Quantitation of phosphorylated tau in the soluble brain homogenate by Western blot using PHF1 for 3xTg mice.
(A) Upper: Western blot using PHF1. Lower: Membrane stained with Fast Green before being probed with PHF1, shown to illustrate that there
was an equal protein load in each of the lanes. (B) Densitometric quantitation of the specific, approximately 60 kDa, PHF1 immunoreactive band,
with a 50% reduction for the pBri-treated 3xTg mice (P < 0.0001 by an unpaired two-tailed t-test). (C) Quantitation of phosphorylated tau (Thr231)
and (D) quantitation of total tau using a Meso Scale Discovery (MSD) system that utilizes electrochemiluminescence analysis. There is a significant
reduction of phosphorylated tau (Thr231; P = 0.019 by two-tailed t-test) of 15%. There is no significant difference in total tau when comparing
pBri-immunized and control 3xTg mice. MSD, Meso Scale Discovery.
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detected by anti-Aβ 4G8 monoclonal antibodies at 1:8000.
The membrane shown in lane 3 was exposed for 60 sec,
the same duration as the membrane shown in lanes 1 and
2. A very faint band can be seen corresponding to dimeric
Aβ, as a minor (<1%) contaminant of the PHF preparation.
The membrane shown in lane 4 was loaded with the same
PHF as in lane 3 but was exposed for 300 sec to reveal the
Aβ species present better. In lane 5, aggregated Aβ1-42
(2 μg) was run and the membrane was detected by 4G8;
the film was exposed for 10 sec and shows a monomer
band as well as higher molecular weight oligomers. The
same PHF sample as run in lanes 2 to 4 was used to coat
the ELISA plates that were used in Figures 2A to D at
50 ng/well. The amount of Aβ in the PHF samples run in
lanes 2 to 4 was estimated to be approximately 100 pg.
This could not be a factor in the ELISA plate reactions
shown in Figures 2A to D, since in the ELISA reactions
against Aβ peptides shown in Figure 1, no coating below
10 ng/well of Aβ gave results above background. An elec-
tron micrograph of the human PHF sample used revealed
the expected paired helical filaments (Figure 2F).
Sensorimotor and cognitive testing
To verify that cognitive testing was not confounded by dif-
ferences in sensorimotor abilities in the pBri-vaccinated
versus control mice, sensorimotor testing was conducted
first in both transgenic lines. There were no significant dif-
ferences between the groups in locomotor activity in
terms of distance traveled, maximum speed, mean velocity
and rest time for TgSwDI mice (data not shown) or for
3xTg mice (data not shown). Traverse beam testing and
rotarod testing also did not reveal any differences between
transgenic controls versus treated transgenic mice for both
the TgSwDI and 3xTg lines (data not shown).
There were statistically significant differences in the re-
sults of the radial arm maze cognitive testing between the
untreated control Tg mice versus the treated Tg mice and
wild-type controls for TgSwDI mice (Figure 3A) and 3xTg
mice (Figure 3B). For TgSwDI mice (Figure 3A) using
two-way ANOVA, the treatment effect had P < 0.001 and
the day effect was not significant. Post hoc Newman–Keuls
testing indicated that both the wild-type controls and
treated Tg mice were significantly different from the con-
trol Tg mice (P < 0.001). There was no difference between
the wild-type controls and the treated Tg mice.
For 3xTg mice (Figure 3B) using two-way ANOVA
the treatment effect had P < 0.001 and the day effect had
P < 0.001. Post hoc Newman–Keuls testing indicated
that both the wild-type controls and treated Tg mice



























Figure 14 Quantitation of astrocytosis in the hippocampus of TgSwDI mice. Reactive astrocytosis was analyzed semiquantitatively on a
scale of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with GFAP from the
hippocampus. (C) Bar graph of astrocyte semiquantitative analysis in the hippocampus for vehicle control and pBri-vaccinated mice. On average
there was a 23% reduction in the areas occupied by GFAP immunoreactivity accounting for astrocytosis (*P = 0.03 by an unpaired two-tailed
t-test). GFAP, glial fibrillary acidic protein; Tg, transgenic.
Goñi et al. Journal of Neuroinflammation 2013, 10:150 Page 13 of 22
http://www.jneuroinflammation.com/content/10/1/150
(P < 0.01). There was no difference between the wild-
type controls and the treated Tg mice.
Amyloid quantitation by stereology and biochemical
analysis
There were significant reductions in the amyloid burden
(percentage area occupied by 4G8/6E10 immunoreac-
tivity) for the treated TgSwDI mice in the hippocampus
(42% reduction, Figure 4), the cortex (70% reduction,
Figure 5) and the amygdala (72% reduction, Figure 6)
with P = 0.039, P = 0.0004 and P < 0.0004, respectively.
Each of the three figures shows a representative section
from a control transgenic mouse, a representative sec-
tion from a pBri-treated transgenic mouse and a histo-
gram of the amyloid burden (scale bar is 200 μm). The
amyloid burdens we calculated for these Tg mice are
similar to what we and others have previously reported
[22,23,29-32]; however, the burdens are less than in
some other reports [33]. This variability is likely related to
differing experimental procedures between laboratories.
There were significant reductions in the amyloid burden
in the hippocampus of treated 3xTg mice (71% reduction,
P = 0.0006, Figure 7). Figure 7A is a representation section
from a control transgenic mouse. Figure 7B is a represen-
tative section from a pBri-treated transgenic mouse and
Figure 7C is a histogram of the amyloid burden (scale
bar is 200 μm). The amyloid burden in the cortex of
these 3xTg mice was too low for meaningful quantita-
tive studies.
Significant reductions in the biochemically extracted
Aβ40 and Aβ42 levels were also noted for both the
TgSwDI and 3xTg mice in the soluble fraction of 20%
brain homogenates (Figure 8). For the TgSwDI mice,
Aβ40 and Aβ42 levels were reduced by 31% and 34%,
respectively (P = 0.02 and P = 0.01, respectively, by un-
paired two-tailed t-tests) (Figure 8A). For the 3xTg
mice Aβ40 and Aβ42 levels were reduced by 55% and
84%, respectively (P < 0.0001 and P = 0.0004, respectively)
(Figure 8B).
Quantitation of Aβ oligomers
Soluble oligomeric/aggregated Aβ ligands (also known
as ADDLs) may account for memory loss and AD
neuropathology, thus they are a significant therapeutic
target [34]. We measured oligomers in the soluble
brain fractions using an ELISA specific to aggregated/
oligomeric Aβ, similar to prior studies by us and others
[20,35,36]. Two-tail unpaired t-tests of this ELISA
showed a significant reduction of levels of Aβ aggre-

























Figure 15 Quantitation of astrocytosis in the cortex of TgSwDI mice. Reactive astrocytosis was analyzed semiquantitatively on a scale of 0 to 4.
Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with GFAP from the cortex. (C) Bar graph of
astrocyte semiquantitative analysis for the cortex of vehicle control and pBri-vaccinated mice. On average there was a 51% reduction in the areas occupied
by GFAP immunoreactivity accounting for astrocytosis (*P= 0.015 by an unpaired two-tailed t-test). GFAP, glial fibrillary acidic protein; Tg, transgenic.
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vehicle group for both TgSwDI mice (Figure 9A, 35%
reduction) and 3xTg mice (Figure 9B, 37% reduction)
(*P = 0.02 and *P = 0.04, respectively, by unpaired two-
tailed t-tests).
Quantification of tau burden in 3xTg mice
To determine the treatment effect of pBri immunomo-
dulation on tau pathology for 3xTg mice, we used a
semiquantitative analysis to quantify the tau burden in
the region of the hippocampus and cortex for the serial
sections as we have previously published [20]. Two
anti-tau antibodies, AT8 (which recognizes tau phos-
phorylated at both serine 202 and threonine 205) and
PHF1 (which recognizes phospho-tau epitopes serine
396 and 404), were used. AT8 immunoreactivity was
observed mainly in the hippocampus of our 3xTg mice,
while PHF1 immunoreactivity was observed in both
the hippocampus and cortex. PHF1 immunoreactivity
was reduced by 74% and 75% in the hippocampus
(Figure 10) and cortex (Figure 11) of pBri-vaccinated
mice, respectively (P = 0.0005 and P = 0.0017 by two-
tailed t-tests, respectively). AT8 immunoreactivity was
reduced by 55% in the hippocampus of pBri-treated
mice (P = 0.03) (Figure 12).
Quantitation of phosphorylated tau in the soluble brain
homogenate by Western blot using PHF1 and Meso
Scale Discovery analysis of total tau and phosphorylated
tau (Thr231)
A PHF1-specific band was noted at approximately 60 kDa
by Western blotting (see arrows in Figure 13A). This band
has been previously reported in 3xTg mice using PHF1;
other bands were also detected but are not specific for
phosphorylated tau [37]. Densitometric quantitation of
this band showed there was a 50% reduction for the pBri-
treated 3xTg mice (see Figure 13B, P < 0.0001 by an un-
paired two-tailed t-test). Figure 13A shows representative
samples from two pBri-treated mice in lanes 1 and 2. A
sample from a 25-month-old 3xTg mouse (with more ex-
tensive tau pathology) was run as a positive control in lane
3. In lane 4, a sample from an age-matched wild-type
mouse was run as a negative control, highlighting that
the other bands seen with PHF1 are not specific for phos-
phorylated tau. Representative samples from two vehicle-
treated 3xTg control mice were run in lanes 5 and 6. A
strong band can be seen at approximately 60 kDa in lanes
5 and 6 (see arrow). This band has about the same inten-
sity as the equivalent band for the positive control, the 25-









Figure 16 Quantitation of astrocytosis in the hippocampus of 3xTg mice. Reactive astrocytosis was analyzed semiquantitatively on a scale
of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with GFAP from the hippocampus.
(C) Bar graph of astrocyte semiquantitative analysis for the hippocampus of vehicle control and pBri-vaccinated mice. On average there was a 24%
reduction in the areas occupied by GFAP immunoreactivity accounting for astrocytosis (*P = 0.03 by an unpaired two-tailed t-test). GFAP, glial
fibrillary acidic protein; Tg, transgenic.
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stronger than the equivalent bands for the pBri-treated
mice in lanes 1 and 2. The membrane stained with Fast
Green shows there was an equal protein load in each of
the lanes.
MSD analysis of phosphorylated tau (Thr231) showed
a significant reduction (P = 0.019) of 15% (Figure 13C),
while the analysis of total tau showed there was no sig-
nificant difference between control and pBri-treated
3xTg mice (Figure 13D).
Assessment of astrocytosis and microglial activation
GFAP immunoreactivity in the hippocampus (Figure 14)
and cortex (Figure 15) for pBri-treated TgSwDI mice
versus control Tg mice was reduced by 23% and 51%, re-
spectively (P = 0.03 and P = 0.015 by two-tailed unpaired
t-tests). GFAP immunoreactivity in the hippocampus
(Figure 16) and cortex (Figure 17) for pBri-treated 3xTg
mice versus control Tg mice was reduced significantly
by 24% and 91%, respectively (P = 0.03 and P = 0.0001 by
two-tailed unpaired t-tests).
The assessment of the microglial marker CD45 was
based on semiquantitative analyses of the extent of micro-
gliosis, as we have previously reported [20,22]. pBri treat-
ment resulted in an overall hippocampal (Figure 18) and
cortical (Figure 19) reduction in CD45 immunoreactivity
for TgSwDI mice of 34% and 42%, respectively (P < 0.05
and P = 0.027 by unpaired one-tailed t-tests). For 3xTg
mice, pBri treatment resulted in a 63% reduction of
CD45 immunoreactivity in the hippocampus (Figure 20,
P = 0.0035 by an unpaired two-tailed t-test). CD45 im-
munoreactivity in the cortex of 3xTg mice was too low
for quantitation.
Quantitation of microhemorrhages by Perl stain in
TgSwDI mice
The number of microhemorrhages in TgSwDI mice was
evaluated by Perl staining as we have previously pub-
lished [22]. No significant differences in microhemor-
rhages were noted in the pBri-treated TgSwDI mice
versus control vehicle-treated Tg mice (Figure 21).
Discussion
We demonstrated that immunization with a non-self-
peptide in a polymerized, β-sheet-rich form in two trans-
genic mice lines, which model either vascular amyloid or
tau-related pathology, is able through conformational
mimicry to induce an immune response to both patho-
logical Aβ42 and PHF. This extends our previous results
that our novel immunomodulatory approach is able to









Figure 17 Quantitation of microgliosis in the cortex of 3xTg mice. Microglial burden was analyzed semiquantitatively on a scale of 0 to 4.
Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with CD45 from the cortex. (C) Bar graph
of microglia semiquantitative analysis for the cortex of vehicle control and pBri-vaccinated mice. On average there was a 91% reduction in the
areas occupied by CD45 immunoreactivity accounting for microgliosis (***P = 0.0001 by an unpaired two-tailed t-test). GFAP, glial fibrillary acidic
protein; Tg, transgenic.
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[16]. Hence, we now show that active immunization with
a non-self-antigen in a conformation that is oligomeric
can be effective at ameliorating all the cardinal lesions of
AD, namely amyloid plaques, congophilic amyloid angio-
pathy and neurofibrillary tangles, without apparent tox-
icity. The immunogen we used corresponds to the 13
amino acids of the carboxyl end of the amyloid that is
deposited in British amyloidosis, where a missense muta-
tion in a stop codon results in the transcription of a
novel intronic sequence [14,15,38]. This peptide has no
homology to known mammalian proteins, but is highly
amyloidogenic [15,39]. This immune response resulted
in a clear behavioral rescue in treated TgSwDI and 3xTg
mice as they performed similarly to wild-type mice in
the radial arm maze. The testing of this cognitive task
was not confounded by any differences in the sensori-
motor activity between the control and vaccinated mice
as shown by the locomotor activity, rotarod and traverse
beam testing, where there were no significant differences
between treated and control Tg mice for both mouse
lines. This behavioral rescue was associated with a
marked reduction in Aβ-related pathology as determined
histologically and biochemically. The anti-Aβ42 and
anti-PHF titers our vaccinated mice developed were
relatively modest; however, as we and others have sug-
gested, behavioral rescue is most closely linked to oligo-
mer reduction and not with either the degree of amyloid
plaque deposition reduction or overall anti-Aβ titer
[40-42]. Hence, it is not the absolute degree of the
humoral response generated to Aβ or tau epitopes but
its quality in terms of effective targeting of toxic species
that is likely the most important factor.
The relatively modest titers also reflect two important
facts about our approach. First, we made a deliberate
choice of aluminum hydroxide (alum) as an adjuvant.
Alum is a relatively mild adjuvant but it is approved for
human use and is widely used [43]. The majority of
immunization studies in AD mouse models have used
much stronger adjuvants that are not approved for use
in humans [32] and also produce a cytotoxic-prone im-
mune response; hence, the results are more difficult to
translate to future human trials. Second, the most toxic
forms of both Aβ and tau are thought to be oligomeric
[9,34]. Importantly we showed that our approach (des-
pite the relatively low titers) was associated with a re-
duction of these toxic oligomer species, as documented
by different assays, one specific to aggregated Aβ species























Figure 18 Quantitation of microglial burden in the hippocampus of TgSwDI mice. Microglial burden was analyzed semiquantitatively on
a scale of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with CD45 from the
hippocampus. (C) Bar graph of microglia semiquantitative analysis for the hippocampus of vehicle control and pBri-vaccinated mice. On average
there was a 34% reduction in the areas occupied by CD45 immunoreactivity accounting for microgliosis (P < 0.05 by an unpaired one-tailed t-test).
Tg, transgenic.
Goñi et al. Journal of Neuroinflammation 2013, 10:150 Page 17 of 22
http://www.jneuroinflammation.com/content/10/1/150
(Figure 13). This is also consistent with our finding using
ELISA for the brain soluble fraction that levels of total
Aβ42 species were more significantly reduced compared
to total Aβ40 species. It is well known that Aβ42 species
are more prone to form oligomers and fibrils. This more
specific targeting of Aβ42 species was most notable for
the 3xTg mice where Aβ42 levels were reduced by 84%,
compared to a 55% reduction of Aβ40 species (see
Figure 8). In addition we demonstrated biochemically
that abnormally phosphorylated tau species identified by
PHF1 (serine 396 and 202) and by MSD (Thr 231) were
reduced by approximately 50% and 15%, respectively, in
the brain soluble fraction, the fraction which contains
tau oligomers (Figure 13). Therefore we document the
reduction of both Aβ and tau oligomeric species by our
immunomodulatory approach. The reduction of tau
pathology is likely to be the result of a combination of
the direct effects of the sustained conformational anti-
PHF immune response to oligomeric forms of tau that
we found (see Figures 2 and 13), as well as an indirect
effect by reducing Aβ oligomers in the pBri 3xTg immu-
nized mice.
The majority of previous active and passive immunization
studies in mouse models and all the previous trials in
humans have targeted both the normal conformer and the
pathological conformer of either Aβ or tau [44]. This can
be problematic as targeting normal sAβ may inhibit its
known physiological functions such as neuroprotection,
modulation of long-term potentiation and innate im-
munity, and there is the risk of inducing autoimmune
complications [45-47]. The targeting of tau by active or
passive immunization also carries the risk of neurotox-
icity and has an encephalogenic potential [44,48]. Our
immunomodulation approach greatly reduces the chance
of such toxicity as the immunogen is a non-self-peptide in
an oligomeric conformation. In an initial human trial of
active vaccination, the use of a self-antigen as an immuno-
gen (Aβ42) was associated with encephalitis in some 6% of
patients [49], which was linked to excess cell-mediated in-
flammation [44,50].
An additional autoimmune complication in ongoing
human trials of passive immunization using anti-Aβ
antibodies has been vasogenic edema or amyloid-related
imaging abnormalities (ARIA), a complication that is
particularly common in apoE4 carriers [51]. The etiology
of ARIA is thought to be directly linked to the removal
of amyloid from CAA lesions in blood vessel walls,
rendering them more likely to undergo leakage or
hemorrhage [52]. CAA occurs in about 98% of AD pa-
tients with approximately 75% of these cases rated as se-
vere CAA [53-55]. In addition, CAA is present in about









Figure 19 Quantitation of microglial burden in the cortex of TgSwDI mice. Microglial burden was analyzed semiquantitatively on a scale of
0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with CD45 from the cortex. (C) Bar
graph of microglia semiquantitative analysis for the cortex of vehicle control and pBri-vaccinated mice. On average there was a 42% reduction in
the areas occupied by CD45 immunoreactivity accounting for microgliosis (*P = 0.027 by an unpaired one-tailed t-test). Tg, transgenic.










Figure 20 Quantitation of microglial burden in the hippocampus of 3xTg mice. Microglial burden was analyzed semiquantitatively on a scale
of 0 to 4. Representative brain sections of both (A) vehicle control and (B) pBri-treated Tg mice immunostained with CD45 from the hippocampus.
(C) Bar graph of microglia semiquantitative analysis for the hippocampus of vehicle control and pBri-vaccinated mice. On average there was a 63%


































Figure 21 Quantitation of microhemorrhaging in the cortex and hippocampus of TgSwDI mice. The number of positive profiles were quantified
per section. Representative Perl-stained brain sections of both (A) vehicle control and (B) pBri-treated Tg mice are shown. Arrows point to Perl positive
profiles. (C) Bar graph of Perl stain semiquantitative analysis depicts no significant difference between Tg controls and pBri-treated 3xTg mice. Tg, transgenic.
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studies have shown a strong correlation between cogni-
tive impairment and the presence of CAA [56-58].
Furthermore, CAA is associated with focal ischemia and
cerebral hemorrhage due to weakening of vascular walls
by amyloid deposits and focal inflammation. Hence, it is
important that we found a marked reduction of CAA
pathology in TgSwDI mice from 42% (in the hippocam-
pus) to 72% (in the amygdala), without an increase in
microhemorrhages or inflammatory toxicity. A caveat is
that CAA in TgSwDI mice is primarily microvascular,
whereas in AD patients amyloid is also found in larger
vessels; however, these microvascular amyloid deposits
are also associated with hemorrhages and correlate more
closely with the presence of dementia [59]. In both
TgSwDI and 3xTg mice there were significant reductions
of astrocytosis and microgliosis as seen by GFAP and
CD45 immunoreactivity. Hence our active immunization
approach, which specifically targets pathological con-
formers only, is effective at lesion reduction without ap-
parent autoimmune complications. It is also notable that
our immunization approach uses alum as an adjuvant.
Alum has been the most widely used human adjuvant
for over 80 years and is regarded as very safe [43]. It pre-
dominantly stimulates humoral immunity, and is much
less likely to be associated with cytotoxic T-cell re-
sponses, which have been linked to toxicity in human
AD vaccination trials [3,43]. Our use of alum as an adju-
vant facilitates the ease with which our approach could
be translated into human trials.
Another significant drawback of the current immunization
approaches being tested in humans is that they target
only Aβ-related pathology. So far none of these trials
has seen a robust clinical improvement, leading some
to question the amyloid cascade hypothesis [13,60,61].
The limited autopsy data from the initial human active
vaccination trial targeting Aβ42 showed that patients
had partial or near complete plaque removal and a re-
duction of Aβ load compared to age-matched non-
immunized controls. However, there were no differ-
ences between placebo and active immunization groups
in the long-term survival outcome, time to severe demen-
tia or in cognitive outcome measurements [60]. Among
living patients taking part in a passive immunization trial
targeting Aβ, a 25% amyloid reduction versus controls was
documented using PET imaging studies, in the absence of
measurable cognitive benefits [61]. It has been suggested
that the failure to produce clear clinical benefits is related
to therapy being started too late in the very long process
of AD pathology accumulation. Aβ and tau-related path-
ology begins to develop up to approximately 25 years be-
fore the onset of obvious clinical signs of even mild
cognitive impairment [62]. Hence, Aβ-directed immuno-
therapy would have to start many years before the patient
is symptomatic to have a greater likelihood of being highly
efficacious. This suggests that for an immunotherapeutic
approach to be effective in symptomatic AD, the interven-
tion should concurrently target both Aβ and tau toxic
conformers specifically. There is a growing consensus re-
garding the importance of specifically targeting both tau
and Aβ soluble aggregates therapeutically [8,9]. We re-
ported the first active immunization approach that could
achieve this goal [16]. Subsequently, another group has de-
veloped an analogous approach using a random sequence
amyloid oligomer mimetic peptide, confirming the validity
of this approach, at least in AD animal models [63,64].
In summary, we found that a novel active immunization
approach, using pBri in an oligomer conformation, is able
to ameliorate all the cardinal lesions of AD pathology,
amyloid plaques, CAA and NFTs, without apparent tox-
icity in different animal models that illustrate each of these
pathologies. Approaches that target pathological protein
conformation have the potential to be effective in a large
spectrum of neurodegenerative diseases.
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